On August 2, 2019, the US government announced several significant changes to hospital antibiotic reimbursement by Medicare & Medicaid (CMS) in US hospitals. Importantly, the new Policy defines rules for reimbursing new antibiotics with Qualified Infectious Disease Product (QIDP) status. This is the most significant pull incentive for antibiotics to date and it will become policy in less than two months from today. Antabio applauds this US initiative that lifts one of the major barriers to investment in antibiotic development, a global unmet need and top WHO priority. To learn more on this initiative visit Health Affairs.
